Appiah John K, Asante Richeal, Ubanatu Chukwunonso B, Blewusi George S, Plange-Kaye Ewurabena, Asiedu Emmanuel K
Internal Medicine, Geisinger Health System, Wilkes-Barre, USA.
Public Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA.
Cureus. 2025 Jun 21;17(6):e86489. doi: 10.7759/cureus.86489. eCollection 2025 Jun.
Background The opioid crisis has evolved beyond overdose deaths to include complex medical complications. Gastrointestinal (GI) complications represent a significant but underexplored aspect of opioid-related mortality. This study aimed to characterize trends in opioid-related deaths with concurrent GI complications in the United States from 2010 to 2020. Methods We conducted a retrospective, population-based analysis using mortality data from the Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research (CDC WONDER) Multiple Cause of Death database and the Global Burden of Disease (GBD) Study 2021. Opioid-related deaths were identified using ICD-10 codes T40.0-T40.4 and T40.6 (opium, heroin, other opioids, methadone, and synthetic and unspecified narcotics) in combination with K25-K28 (peptic ulcers), K56.0-K56.7 (intestinal obstruction), K59.0 (constipation), and K92.0-K92.2 (GI hemorrhage). Background GI mortality rates were obtained from GBD. Crude and age-adjusted mortality rates were calculated, and trends were analyzed using descriptive statistics. Results From 2010 to 2020, opioid-related deaths with GI complications increased by 218.6%, from 22,040 deaths (7.15 per 100,000) to 70,222 deaths (21.31 per 100,000). Males experienced disproportionately higher mortality rates (16.31 per 100,000) compared to females (7.76 per 100,000). West Virginia demonstrated the highest mortality rate (37.85 per 100,000), followed by Ohio (23.48 per 100,000) and Maryland (23.19 per 100,000). The steepest increases occurred between 2015 and 2017, with an unprecedented surge in 2020. Conclusions Opioid-related deaths with concurrent GI complications represent a rapidly escalating public health crisis, with mortality rates more than tripling over the study decade. The disproportionate impact on males and concentration in Appalachian and Rust Belt states suggest that targeted interventions are urgently needed.
阿片类药物危机已从过量用药死亡演变为包括复杂的医学并发症。胃肠道(GI)并发症是阿片类药物相关死亡率的一个重要但未得到充分研究的方面。本研究旨在描述2010年至2020年美国伴有胃肠道并发症的阿片类药物相关死亡趋势。方法:我们使用疾病控制和预防中心广泛在线流行病学研究数据(CDC WONDER)多死因数据库和2021年全球疾病负担(GBD)研究中的死亡率数据进行了一项基于人群的回顾性分析。使用国际疾病分类第十版(ICD-10)编码T40.0-T40.4和T40.6(鸦片、海洛因、其他阿片类药物、美沙酮以及合成和未指定的麻醉品)与K25-K28(消化性溃疡)、K56.0-K56.7(肠梗阻)、K59.0(便秘)和K92.0-K92.2(胃肠道出血)来确定阿片类药物相关死亡。胃肠道死亡率数据来自全球疾病负担研究。计算了粗死亡率和年龄调整死亡率,并使用描述性统计分析趋势。结果:2010年至2020年,伴有胃肠道并发症的阿片类药物相关死亡增加了218.6%,从22040例死亡(每10万人中有7.15例)增至70222例死亡(每10万人中有21.31例)。男性的死亡率(每10万人中有16.31例)比女性(每10万人中有7.76例)高得多。西弗吉尼亚州的死亡率最高(每10万人中有37.85例),其次是俄亥俄州(每10万人中有23.48例)和马里兰州(每10万人中有23.19例)。增长最陡峭的时期是2015年至2017年,2020年出现了前所未有的激增。结论:伴有胃肠道并发症的阿片类药物相关死亡代表着一场迅速升级的公共卫生危机,在研究的十年间死亡率增加了两倍多。对男性的影响不成比例以及在阿巴拉契亚和铁锈地带各州的集中情况表明,迫切需要有针对性的干预措施。